美股
Lead report
Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 (NASDAQ:PHAT)
Phathom Pharma (PHAT) Q2 2026 earnings call: VOQUEZNA growth, first operating profit, lower revenue guidance on payer friction, and pipeline updatesâread...
